Information
Nanoligent is a preclinical-stage biotech company based in Barcelona, focused on developing precision nanomedicines designed to selectively target and eliminate tumor cells that overexpress the CXCR4 receptor—a well-researched target in oncology with no aproved drug therapy yet. Our innovative technology has demonstrated efficacy in both liquid and solid tumor animal models, positioning Nanoligent to deliver an anticancer treatment that addresses the limitations of current therapies. We are currently raising capital to advance our lead candidate into clinical trials.
Key Information
-
Series A
Growth Stage
-
CountrySpain
-
Founding Year2017